Is Ciba On The Prowl?

With President Clinton's drive for health-care reform squeezing pharmaceutical makers' profit margins, Swiss drugmaker Ciba-Geigy Ltd. is hinting that it may put some of its $1 billion cash hoard to work shoring up its competitive position in the U.S. Chairman Alex Krauer says Ciba is "exploring very carefully and systematically" whether it should "join forces with other pharmaceutical companies," or take over a big drug distributor, as competitor Merck recently did with Medco Containment Services. "Just continuing to do business as we have in the past is no solution," Krauer said in an interview.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.